MAPK pathway activation in colorectal cancer: a therapeutic opportunity for GRP receptor antagonists.
Faculty of Medicine, Federal University of Rio Grande do Sul, and South American Office for Anticancer Drug Development, 90035-003 Porto Alegre, RS, Brazil. gschwartsmann@hcpa.ufrgs.br
Gilberto
G
Schwartsmann
Luciane Pons
LP
Di Leone
Felipe
F
Dal Pizzol
Rafael
R
Roesler
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001839:Bombesin / Q000031:analogs & derivatives / Q000494:pharmacology; D015179:Colorectal Neoplasms / Q000378:metabolism*; D016503:Drug Delivery Systems; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D010446:Peptide Fragments / Q000494:pharmacology; D051381:Rats; D018004:Receptors, Bombesin / Q000037:antagonists & inhibitors / Q000187:drug effects* / Q000502:physiology
D000970:Antineoplastic Agents; D010446:Peptide Fragments; D018004:Receptors, Bombesin; C071363:bombesin (6-14), Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)-; D001839:Bombesin